Technical Analysis for TLC - Taiwan Liposome Company, Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Very Strong | N/A | Down | Flat |
| See historical TLC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | -1.85% | |
| Crossed Above 50 DMA | Bullish | -1.85% | |
| Upper Bollinger Band Touch | Strength | -1.85% | |
| 20 DMA Resistance | Bearish | -0.17% | |
| Gapped Up | Strength | -0.17% | |
| Narrow Range Bar | Range Contraction | -0.13% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Taiwan Liposome Company, Ltd., a biopharmaceutical company, engages in the research, development, and commercialization of lipid-based pharmaceutical products. The company offers products in the areas of oncology, ophthalmology, peripheral arterial disease, fungal infection, anesthetic, and arthritis indications. Its products include Lipotecan, an anti-cancer camptothecin drug; Doxisome, a liposomal encapsulated formulation of doxorubicin; TLC178, a liposomal encapsulated formulation of vinorelbine; ProDex, an ophthalmic drug for the treatment of macular edema; ProFlow, an emulsion form of prostaglandin E1; AmBiL, a liposomal encapsulated formulation of amphotericin B; TLC198, a liposomal encapsulated bupivacaine, enabling the sustained release of a constant amount of local anesthetic; and TLC599, a corticosteroid encapsulated in lipid based drug delivery system for the treatment of inflammation caused by arthritis. The company was founded in 1997 and is headquartered in Taipei City, Taiwan.
Biopharmaceutical Drugs Inflammation Pharmacology Drug Delivery Arthritis Macular Edema Doxorubicin Peripheral Arterial Disease Amphotericin B Arbutus Biopharma Bupivacaine Liposome
Biopharmaceutical Drugs Inflammation Pharmacology Drug Delivery Arthritis Macular Edema Doxorubicin Peripheral Arterial Disease Amphotericin B Arbutus Biopharma Bupivacaine Liposome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more TLC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 11.0 |
| 52 Week Low | 5.02 |
| Average Volume | 3,741 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 5.921 |
| 20-Day Moving Average | 5.8426 |
| 10-Day Moving Average | 5.8312 |
| Average True Range | 0.1536 |
| ADX | 53.86 |
| +DI | 33.6512 |
| -DI | 10.4791 |
| Chandelier Exit (Long, 3 ATRs ) | 5.6392 |
| Chandelier Exit (Short, 3 ATRs ) | 6.1608 |
| Upper Bollinger Band | 5.9497 |
| Lower Bollinger Band | 5.7355 |
| Percent B (%b) | 0.39 |
| BandWidth | 3.666176 |
| MACD Line | -0.0244 |
| MACD Signal Line | -0.0374 |
| MACD Histogram | 0.013 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.82 | ||||
| Resistance 3 (R3) | 5.82 | 5.82 | 5.82 | ||
| Resistance 2 (R2) | 5.82 | 5.82 | 5.82 | 5.82 | |
| Resistance 1 (R1) | 5.82 | 5.82 | 5.82 | 5.82 | 5.82 |
| Pivot Point | 5.82 | 5.82 | 5.82 | 5.82 | 5.82 |
| Support 1 (S1) | 5.82 | 5.82 | 5.82 | 5.82 | 5.82 |
| Support 2 (S2) | 5.82 | 5.82 | 5.82 | 5.82 | |
| Support 3 (S3) | 5.82 | 5.82 | 5.82 | ||
| Support 4 (S4) | 5.82 |
